Rosiglitazone promotes cardiac hypertrophy and alters chromatin remodeling in isolated cardiomyocytes

LF Pharaon, NF El-Orabi, M Kunhi, N Al Yacoub… - Toxicology letters, 2017 - Elsevier
Rosiglitazone is an anti-diabetic agent that raised a major controversy over its
cardiovascular adverse effects. There is in vivo evidence that Rosiglitazone promotes
cardiac hypertrophy by PPAR− γ-independent mechanisms. However, whether
Rosiglitazone directly alters hypertrophic growth in cardiac cells is unknown. Chromatin
remodeling by histone post-translational modifications has emerged as critical for many
cardiomyopathies. Based on these observations, this study was initiated to investigate the …